Introduction
============

Spondyloarthritis (SpA) is a group of chronic inflammatory rheumatic diseases with pathophysiological, clinical, radiological and genetic features of inflammatory back pain with or without peripheral arthritis, combined with certain features of extra-articular manifestations. Diseases in this category include ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, arthropathy of inflammatory bowel disease, undifferentiated SpA and juvenile chronic arthritis ([@b1-etm-0-0-5003]--[@b3-etm-0-0-5003]). As SpA diseases progress they can develop into AS, which is the most severe and common subtype of SpA. The primary clinical symptoms of AS include pain, joint stiffness and loss of spinal mobility, which can result in severe impairment of function and a decrease in the patient\'s quality of life ([@b4-etm-0-0-5003],[@b5-etm-0-0-5003]).

The primary treatments for patients with SpA include general drug treatments accompanied with physiotherapy. However, short-term corticosteroids, conventional non-steroidal anti-inflammatory drugs and disease modifying anti-rheumatic drugs, including methotrexate and sulfasalazine, have not proved to be particularly effective for the treatment of SpA while causing a high incidence of side effects ([@b6-etm-0-0-5003]--[@b8-etm-0-0-5003]). Tumor necrosis factor (TNF)-α, a pleiotropic cytokine that is produced during the inflammatory response, serves an important role in the pathogenesis of numerous chronic inflammatory and rheumatic diseases ([@b9-etm-0-0-5003]). The therapies used for the treatment of SpA have undergone a drastic revision since the development of anti-TNF agents, which inhibit and prevent TNF-α from promoting inflammation, and therefore are beneficial for alleviating the symptoms of SpA ([@b10-etm-0-0-5003]).

While anti-TNF biologics improve the function and quality of life of patients with SpA, suppressing the immune system makes patients more susceptible to infections. This is the most adverse effect of anti-TNF agent therapy, and has been demonstrated to be significantly higher in patients with SpA, particularly AS, treated with anti-TNF agents compared with those receiving non-biological treatments ([@b11-etm-0-0-5003]). Serious infection, whilst rare, is severe and thus the inhibitory effects of anti-TNF therapy on the immune response are important. Considering that anti-TNF agents usually require long-term application in patients with SpA and AS ([@b10-etm-0-0-5003],[@b12-etm-0-0-5003]), a meta-analysis was performed to investigate whether the risk of serious infection, including tuberculosis, is increased in patients with SpA or AS treated with anti-TNF agents. In addition, the overall infection rate in patients with SpA or AS was investigated.

Materials and methods
=====================

### Data sources and search strategy

The design of the present meta-analysis was prepared in accordance with the preferred reporting items for systematic reviews and meta-analyses statement ([@b13-etm-0-0-5003]). Medline (<http://www.ncbi.nlm.nih.gov>), Embase (<http://www.embase.com>) and the Cochrane Library (<http://www.cochranelibrary.com>) were searched for publications from January 1998 to December 2015 with the following terms: 'Spondyloarthritis', 'ankylosing spondylitis', 'psoriatic arthritis' or 'reactive arthritis' combined with 'biologics', 'anti-TNF agent' or the names of specific biologic agents, including 'etanercept', 'infliximab', 'adalimumab', 'certolizumab pegol', 'golimumab', and combined with 'adverse reaction' and 'infection'. Searches were restricted to English language publications and studies in humans. The search was supplemented by manual searches of the proceedings of the American College of Rheumatology (<http://www.rheumatology.org>) and the European League Against Rheumatism (<http://www.eular.org>). Meanwhile, to identify all relevant articles, the reference lists from associated reviews and meta-analyses were also searched manually.

### Study selection

Randomized controlled trials (RCTs) comparing anti-TNF agents with placebos (or other medications), alone or in combination, in patients with SpA were identified. The inclusion and exclusion criteria were as described below. i) Study design: The study must be an RCT; for trials with a cross-over design, a double-blind period followed by an open-label period was eligible for inclusion, while studies with a Jadad score \<3 were excluded. ii) Participants: The enrolled patients must fulfill the assessment of SpA criteria for peripheral SpA and SpA in general ([@b14-etm-0-0-5003]), and patients who were suffering from chronic infections at the beginning of experiments were excluded. iii) Intervention: Studies comparing treatment with infliximab, etanercept, adalimumab, golimumab and certolizumab pegol, either alone or in combination with other medications, against a control group were included; trials using a single infusion or injection of an anti-TNF agent were excluded. Additionally, the duration of the placebo-controlled phases across trials were limited to short term. iv) Endpoints: All included articles must demonstrate the outcomes associated with infection. Studies were independently screened and selected by two investigators, and discrepancies were resolved through discussion.

### Data extraction and quality assessment

Using a preformed form, data were extracted by two independent investigators with any discrepancies resolved by discussion. In addition to general information, including the first author, publication year, study design, underlying disease, interventions, study duration, sample size and other specific circumstances, the present study focused on extracting outcomes of the events, including the occurrence of overall infection, serious infection and tuberculosis. For the studies that included a double-blind period and an open-labeled period, only the result of the double-blind period was extracted. Notably, in one trial of etanercept with administration of 25 mg twice a week or 50 mg once a week, the decision was made to present the combined results as these regimens were demonstrated to be equivalent in terms of benefit and safety ([@b15-etm-0-0-5003]). Selected studies were critically appraised for quality based on the Jadad scale ([@b16-etm-0-0-5003]).

### Statistical analysis

Extracted data were analyzed using the Mantel-Haenszel method with Review Manager software (version 5.2, The Cochrane Collaboration, Copenhagen, Denmark). The Q test and I^2^ statistics were used to evaluate the heterogeneity of the RCTs in accordance with the Cochrane Handbook ([@b17-etm-0-0-5003]). An I^2^ value of \>50% accompanied with a P-value \<0.05 for the Q test was determined to indicate the presence of significant heterogeneity. When there was no significant heterogeneity, a fixed effects model was used; otherwise a random effects model was applied. Forest plots were constructed to display relative risk (RR) estimates and 95% confidence intervals (CIs). Funnel plots were assessed for evidence of asymmetry, followed by possible publication bias or other small study effects. Subgroup analysis was performed to explore potential differences by stratifying different anti-TNF agents in patients with SpA and AS. For sparse data on serious infection, due to null values in either the intervention or control arms in several trials, either a crude analysis was performed by combining study results, or the studies were excluded, according to the methodological description by Bradburn *et al* ([@b18-etm-0-0-5003]). Sensitivity analysis was also performed to inspect the robustness of the data using Stata software (version 12.0, StataCorp LP, College Station, TX, USA).

Results
=======

### Study selection and characteristics

A flow diagram depicting the process of searching and selecting RCTs was presented in [Fig. 1](#f1-etm-0-0-5003){ref-type="fig"}. A total of 1,621 unique RCTs were obtained after removing duplicates from the initial search that identified 1,744 studies. Of these studies, 1,526 were excluded through reading the title and abstract. Via a detailed full-text review of the remaining 95 studies, 26 articles were retrieved for evaluation. With 1 study eliminated due to a Jaded score below the cutoff level of 3 ([@b19-etm-0-0-5003]), ultimately 25 articles were eligible for inclusion in the analysis ([@b2-etm-0-0-5003],[@b15-etm-0-0-5003],[@b20-etm-0-0-5003]--[@b42-etm-0-0-5003]). Notably, 2 trials ([@b29-etm-0-0-5003],[@b42-etm-0-0-5003]) that were not double-blind were included in the primary analysis, though the quality of their Jadad scores was not particularly high. Among the 25 articles eligible for analysis, 12 studies were investigating patients with AS.

[Table I](#tI-etm-0-0-5003){ref-type="table"} listed the general characteristics of the 25 articles included in the present study. With regards to the anti-TNF agents utilized, 9 trials used etanercept, 7 used infliximab, 7 used adalimumab and 2 used golimumab. No RCTs investigating certolizumab pegol were eligible for analysis due to their inadequate presentation of infection outcomes ([@b43-etm-0-0-5003]--[@b45-etm-0-0-5003]). The quality of the eligible studies met the required standards, with a mean Jadad score of 5.80±1.04. The duration of placebo-controlled phases across trials ranged from 12 to 48 weeks. In addition, the dosages of the biologics used in these RCTs met US Food and Drug Administration standards.

### Overall infection rate of patients with SpA or AS receiving anti-TNF agents vs. a placebo

In the 25 studies identified, 564/2,534 patients with SpA (22.3%) who received anti-TNF agents and 369/1,685 patients with SpA (21.9%) who received a placebo experienced an infection. Thus, no significant difference was identified in the infection rate between patients with SpA treated with anti-TNF agents compared with those who received a placebo (RR, 1.03; 95% CI, 0.92--1.15; [Fig. 2](#f2-etm-0-0-5003){ref-type="fig"}). The risk of overall infection was then stratified by the type of anti-TNF agent. No significant differences were observed in the infection rate between patients with SpA treated with a specific anti-TNF agent compared with a placebo. The individual results were as follows: Etanercept (RR, 0.97; 95% CI, 0.81--1.16); infliximab (RR, 1.11; 95% CI, 0.88--1.40); adalimumab (RR, 1.02; 95% CI, 0.84--1.24); and golimumab (RR, 3.00; 95% CI, 0.42--21.65) ([Fig. 2](#f2-etm-0-0-5003){ref-type="fig"}).

Among the RCTs evaluated, 12 investigated patients with AS. The incidence of infection in these studies was similar between the groups treated with anti-TNF agents (374/1,618 patients; 23.1%) and the control (187/816 patients; 22.9%). There was no significant difference in the overall rate of infection between these groups (RR, 1.06; 95% CI, 0.91--1.24; [Fig. 3](#f3-etm-0-0-5003){ref-type="fig"}). Subgroup analysis by the type of anti-TNF agent used also revealed no significant differences, with the following individual results: Etanercept (RR, 0.95; 95% CI, 0.77--1.19); infliximab (RR, 1.08; 95% CI, 0.81--1.44); adalimumab (RR, 1.27; 95% CI, 0.92--1.24); and golimumab (RR, 3.00; 95% CI, 0.42--21.65) ([Fig. 3](#f3-etm-0-0-5003){ref-type="fig"}).

### Serious infection rate of patients with SpA or AS receiving anti-TNF agents vs. a placebo

A total of 19/2,534 patients with SpA (0.75%) treated with anti-TNF agents had a serious infection compared with 9/1,685 patients (0.53%) who received a placebo. By pooling the data crudely, the relative risk of serious infection in patients with SpA treated with anti-TNF agents compared with the control group was 1.40 (95% CI, 0.64--3.10). After discarding the null studies, 17 RCTs were evaluated. Compared with patients treated with a placebo, patients receiving anti-TNF agents did not have a significantly increased risk of serious infection (RR, 1.27; 95% CI, 0.67--2.38; [Fig. 4](#f4-etm-0-0-5003){ref-type="fig"}). The subgroup analysis that stratified the studies based on the anti-TNF agent used did not identify any significant heterogeneity compared with the control group either. The results were as follows: Etanercept (RR, 1.33; 95% CI, 0.46--3.85); infliximab (RR, 2.27; 95% CI, 0.68--7.54); and adalimumab (RR, 0.67; 95% CI, 0.22--2.06) ([Fig. 4](#f4-etm-0-0-5003){ref-type="fig"}).

Similarly, in the 12 RCTs investigating patients with AS, 12/1,618 patients (0.74%) who received anti-TNF agent therapy experienced serious infection compared with 3/816 patients (0.37%) in the control group. This crude pooled result demonstrated that anti-TNF agents did not significantly increase the risk of serious infection in patients with AS (RR, 2.02; 95% CI, 0.57--7.13). After the 4 null RCTs abandoned, 8 studies were eligible for further analysis. The meta-analysis demonstrated that anti-TNF agents resulted in a 1.57-fold higher risk of serious infection in patient with AS compared with the control group (RR, 1.57; 95% CI, 0.63--3.91; [Fig. 5](#f5-etm-0-0-5003){ref-type="fig"}). Individually, etanercept resulted in a 2.23-fold higher likelihood of serious infection (RR, 2.23; 95% CI, 0.49--10.10) and infliximab in a 2.42-fold higher likelihood (RR, 2.42; 95%, CI, 0.27--21.24), while adalimumab reduced the risk of serious infection (RR, 0.87; 95% CI, 0.21--3.61) ([Fig. 5](#f5-etm-0-0-5003){ref-type="fig"}). However, none of these results were statistically significant.

### Rate of tuberculosis infection in patients with SpA receiving anti-TNF agents vs. a placebo

In the 25 RCTs included in the present study, only 4 studies revealed incidences of tuberculosis, which all emerged in infliximab-treated patients with SpA ([Fig. 6](#f6-etm-0-0-5003){ref-type="fig"}). Thus, infliximab treatment resulted in a 2.42-fold higher likelihood of tuberculosis in patients with SpA compared with the control group (RR, 2.42; 95% CI, 0.40--14.70); however, this result was not significant ([Fig. 6](#f6-etm-0-0-5003){ref-type="fig"}). In addition, due to the limited number of RCTs, this finding should be interpreted with caution.

### Publication bias

Funnel plots were produced to assess the publication bias of the included studies. The shape of funnel plots revealed no obvious asymmetry ([Fig. 7](#f7-etm-0-0-5003){ref-type="fig"}), indicating that there was no publication bias for the overall and serious infection outcomes identified in patients with SpA or AS.

### Sensitivity analysis

Sensitivity analysis was performed by omitting individual studies to evaluate the robustness of the data. The results revealed that the RR was not influenced meaningfully in each model ([Fig. 8](#f8-etm-0-0-5003){ref-type="fig"}). Notably, the 2 studies that were not double-blinded trials did not influence the robustness of the present study.

Discussion
==========

Presently, there are five anti-TNF agents available for the treatment of SpA, which are divided into three categories ([@b46-etm-0-0-5003],[@b47-etm-0-0-5003]). One category includes etanercept, a soluble receptor of the p75 TNF receptor/Fc fusion protein. Another category includes the monoclonal antibodies infliximab, adalimumab and golimumab. Infliximab is composed of a murine variable region and human constant region, while adalimumab and golimumab are human antibodies. The last category includes certolizumab pegol, a recombinant humanized antibody of the Fab region conjugated to polyethylene glycol. The use of these drugs is a double-edged sword, as suppressing the immune response improved the symptoms of patients with SpA but also increased the risk of infection ([@b48-etm-0-0-5003]--[@b52-etm-0-0-5003]). To the best of our knowledge, the present meta-analysis was the first and largest review examining the risk of infection in patients with SpA treated with anti-TNF agents in RCTs. In AS, a meta-analysis was published to assess serious infection in patients receiving TNF blockers in 2010 ([@b53-etm-0-0-5003]). Considering more single studies arising published after 2010 ([@b21-etm-0-0-5003],[@b35-etm-0-0-5003],[@b38-etm-0-0-5003]) and the absence of data identifying respective risk of different anti-TNF agents in the previous meta-analysis, an updated meta-analysis regarding serious infection with use of TNF inhibitors for AS was performed in the present study.

The results of the present study revealed that there was no increased risk of overall infection with the short-term use of anti-TNF agents for patients with SpA or AS. Among the studies identified, the majority of reported infections were minor, particularly upper respiratory tract infections. With regard to the risk of serious infection, the crude pooled result did not find an increased risk in patients with SpA or AS treated with anti-TNF agents. For the risk of serious infection in patients with AS, the result of the present study was in accordance with the previous meta-analysis ([@b53-etm-0-0-5003]). However, compared with the prior meta-analysis, the present study had certain advantages. Firstly, the estimates were based on the pooling of 12 RCTs with an overall population of 2,434 participants compared with the prior study\'s sample size of 1,496 patients. With the large number of patients and similar results to the previous meta-analysis, it was unlikely that new individual RCTs would affect the conclusion of the present analysis. In addition, the present study brought golimumab into the meta-analysis and performed a subgroup analysis to explore the individual risk of infection from each anti-TNF agent. Furthermore, since SpA may develop into AS, in the meta-analysis, we didn\'t simply limit to the disease of AS and severity of infection, which could lead to a more comprehensive understanding and comparison as diseases progresses. Overall, the present study provided further support to the existing observational data, and was an updated and extended meta-analysis with detailed outcomes for infection.

On account of its seriousness and infectivity, tuberculosis was also an outcome that the present study investigated in patients with SpA treated with anti-TNF agents. In the analysis conducted in the current study, only 4 incidences of tuberculosis were detected in anti-TNF agent-treated patients with SpA, with the anti-TNF agent being infliximab in all cases. Certain previous studies have demonstrated that the incidence of tuberculosis is 3--4 times higher in patients with SpA receiving monoclonal antibody anti-TNF agents compared with those receiving etanercept ([@b54-etm-0-0-5003],[@b55-etm-0-0-5003]), which may be associated with the different mechanisms of tuberculosis infection. Saliu *et al* ([@b56-etm-0-0-5003]) reported that adalimumab and infliximab reduced the proportion of tuberculosis-responsive cluster of differentiation (CD)69^+^ CD4 cells by 50--70% and suppressed antigen-induced interferon γ production in an *in vitro* intracellular infection model; however, etanercept had no significant effect. A Markov model performed by Wallis ([@b57-etm-0-0-5003]) revealed that infliximab-associated tuberculosis occurred within a very short time after taking the medicine (12--21 weeks), whereas infection onset was 3--5 times later with etanecept. In addition, the risk of latent tuberculosis recurrence after infliximab was 12.1 times higher compared with etanecept ([@b57-etm-0-0-5003]). These results indicated that anti-TNF agents should be carefully selected and that tuberculosis should be screened for in a timely manner in the clinical practice of patients with SpA.

The present analysis had several limitations. The study search was limited to papers published in English, which may have excluded other relevant non-English language studies and affected the results. However, all large RCTs were included, so the exclusion of several small trials should not have altered the results. In addition, no publication bias was identified for any condition. Another limitation was that serious infection was determined according to each RCTs definition, which would increase heterogeneity to a certain extent. However, the sensitivity analysis performed would have minimized the role of such heterogeneity. In addition, due to the rarity of serious infection, and the short duration of treatment and follow-up, the present study did not assess the risk of serious infection stratified by follow-up time.

In conclusion, the results of the present meta-analysis suggest that there is not a significantly increased risk of infection in patients with SpA or AS receiving anti-TNF agent therapy. However, since anti-TNF agents typically need to be used for a long period of time, even lifelong, in patients with SpA, particularly AS, more long-term follow-up studies are required to confirm the findings of the present study, in addition to exploring the potential occurrence of tuberculosis.
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###### 

Characteristics of the studies included in the meta-analysis investigating the use of anti-TNF agents in patients with SpA or AS.

                                 Anti-TNF group   Control group                                                                                                 
  ------------------------------ ---------------- --------------- --------------------------------------- ------ ----- --- --- ----------- ------ ----- --- --- -----------------------
  Dougados *et al*, 2014         axSpA            12              ETA 50 mg Qw                            106    11    0   0   PBO         109    10    1   0   ([@b20-etm-0-0-5003])
  Braun *et al*, 2010            AS               16              ETA 50 mg Qw                            379    43    0   0   SSZ         187    26    0   0   ([@b21-etm-0-0-5003])
  Dougados *et al*, 2010         SpA              12              ETA 50 mg Qw                              12     5   1   0   PBO           12     1   0   0   ([@b22-etm-0-0-5003])
  van der Heijde *et al*, 2006   AS               12              ETA 50 mg Qw or 25 mg Biw               305    68    2   0   PBO           51   12    0   0   ([@b15-etm-0-0-5003])
  Mease *et al*, 2004            PsA              24              ETA 25 mg Biw                           101    33    0   0   PBO         104    39    1   0   ([@b23-etm-0-0-5003])
  Calin *et al*, 2004            AS               12              ETA 25 mg Biw                             45     0   0   0   PBO           39     0   0   0   ([@b24-etm-0-0-5003])
  Davis *et al*, 2003            AS               24              ETA 25 mg Biw                           138    44    2   0   PBO         139    43    1   0   ([@b25-etm-0-0-5003])
  Brandt *et al*, 2003           AS               24              ETA 25 mg Biw                             14     6   0   0   PBO           16     6   0   0   ([@b26-etm-0-0-5003])
  Gorman, 2002                   AS               16              ETA 25 mg Biw                             20   12    2   0   PBO           20   12    0   0   ([@b27-etm-0-0-5003])
  Sieper *et al*, 2013           axSpA            24              IFX 5 mg/kg+NPX 0, 2, 6, 12, 18, 24 w   105    27    1   1   PBO + NPX     52     9   0   0   ([@b28-etm-0-0-5003])
  Baranauskaite *et al*, 2011    PsA              16              IFX 5 mg/kg+MTX 0, 2, 6, 14 w             57     4   2   1   MTX           54     0   0   0   ([@b29-etm-0-0-5003])
  Marzo-Ortega *et al*, 2005     AS               30              IFX 5 mg/kg+MTX 0, 2, 6, 14, 22 w         28     6   0   0   PBO + MTX     14     2   0   0   ([@b30-etm-0-0-5003])
  van der Heijde *et al*, 2004   AS               24              IFX 5 mg/kg 0, 2, 6, 12, 18 w           201    86    2   0   PBO           78   27    0   0   ([@b31-etm-0-0-5003])
  Antoni *et al*, 2004           PsA              16              IFX 5 mg/kg 0, 2, 6, 14 w                 52     9   1   0   PBO           51   16    1   0   ([@b32-etm-0-0-5003])
  Van Den Bosch *et al*, 2002    SpA              12              IFX 5 mg/kg 0, 2, 6 w                     20     9   1   1   PBO           20     6   0   0   ([@b33-etm-0-0-5003])
  Braun *et al*, 2002            AS               12              IFX 5 mg/kg 0, 2, 6 w                     34   12    1   1   PBO           35   18    0   0   ([@b34-etm-0-0-5003])
  Mease *et al*, 2015            npSpA            12              ADA 40 mg Eow                             84   18    0   0   PBO           81   23    0   0   ([@b2-etm-0-0-5003])
  Huang *et al*, 2013            AS               12              ADA 40 mg Eow                           229    25    1   0   PBO         115    12    0   0   ([@b35-etm-0-0-5003])
  Sieper *et al*, 2012           axSpA            12              ADA 40 mg Eow                             91   28    0   0   PBO           94   28    0   0   ([@b36-etm-0-0-5003])
  Paramarta *et al*, 2012        SpA              12              ADA 40 mg Eow                             20     4   0   0   PBO           20     8   1   0   ([@b37-etm-0-0-5003])
  Horneff *et al*, 2012          Jo-AS            12              ADA 40 mg Eow                             17     6   2   0   PBO           15     6   1   0   ([@b38-etm-0-0-5003])
  van der Heijde *et al*, 2006   AS               24              ADA 40 mg Eow                           208    66    0   0   PBO         107    23    1   0   ([@b39-etm-0-0-5003])
  Mease *et al*, 2005            PsA              24              ADA 40 mg Eow                           151    36    1   0   PBO         162    41    2   0   ([@b40-etm-0-0-5003])
  Sieper *et al*, 2015           axSpA            16              GLM 50 mg Q4w                             97     0   0   0   PBO         100      0   0   0   ([@b41-etm-0-0-5003])
  Mok *et al*, 2015              axSpA            48              GLM 50 mg Q4w                             20     6   0   0   PAM           10     1   0   0   ([@b42-etm-0-0-5003])

ETA, etanercept; IFX, infliximab; ADA, adalimumab; GLM, golimumab; PBO, placebo; MTX, methotrexate; NPX, naproxen; SSZ, sulfasalazine; PAM, pamidronate; P, participant; I, infection; SI, serious infection; TB, tuberculosis; n, number; w, week; Qw, once weekly; Biw, twice weekly; Eow, every other week; Q4w, every 4 weeks; SpA, spondyloarthritis; AS, ankylosing spondylitis; axSpA, axial SpA; PsA, psoriatic arthritis; npSpA, nonpsoriatic peripheral SpA; Jo-AS, juvenile onset AS.
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